ANTIANDROGEN MONOTHERAPY MARKET ANALYSIS

Antiandrogen Monotherapy MarketSize and Trends

Global Antiandrogen Monotherapy Market – Dynamics

The increasing approvals of new antiandrogen monotherapy drugs by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in December 2019, Pfizer Inc. and Astellas Pharma Inc. received approval for a supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for XTANDI (enzalutamide), indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Moreover, increasing prevalence of prostate cancer is likely to propel growth of the antiandrogen monotherapy market over the forecast period. According to the World Cancer Research Fund, prostate cancer is the second most common cancer diagnosed in males and fourth most common cancer occurring overall. The World Cancer Research Fund also estimated that around 1.3 million males were diagnosed with prostate cancer globally in 2018. Such high prevalence of prostate cancer is expected to increase demand for antiandrogen monotherapy in order to treat the disease.

Global Antiandrogen Monotherapy Market – Trends

Moreover, the antiandrogen monotherapy market is likely to grow due to technological advancements and increasing research and development activities in the field of prostate cancer treatment.

Global Antiandrogen Monotherapy Market – Market Trends

The rising awareness regarding the availability of advanced treatments and the benefits of antiandrogen monotherapy is also expected to drive the market growth over the forecast period.